SAT-100 Trial-in-Progress: ZEPHYR, a Pivotal Phase 2b/3 Randomized, Placebo-Controlled Study of Livoletide, a Novel Unacylated Ghrelin Analog, for the Treatment of Hyperphagia and Food-Related Behaviors in Patients with Prader-Willi Syndrome

Background: Prader-Willi syndrome (PWS) is a rare and complex endocrine disease characterized by hyperphagia and abnormal food-related behaviors that contribute to severe morbidity and early mortality and to a significant burden on patients and caregivers. There is no approved treatment for hyperpha...

Descripción completa

Detalles Bibliográficos
Autores principales: Allas, Soraya, Mohideen, Pharis, Delale, Thomas, Lin, Vivian, Tremel, Nadege, Yeh, Michael, Tauber, Maithe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Adipose Tissue, Appetite, and Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552513/
http://dx.doi.org/10.1210/js.2019-SAT-100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552513/
http://dx.doi.org/10.1210/js.2019-SAT-100

Ejemplares similares